tiprankstipranks
AEON Biopharma Phase 2 Migraine Treatment Trial Results
Company Announcements

AEON Biopharma Phase 2 Migraine Treatment Trial Results

Don't Miss our Black Friday Offers:

AEON Biopharma (AEON) just unveiled an announcement.

AEON Biopharma, Inc. revealed preliminary findings from a Phase 2 trial of ABP-450, a potential chronic migraine preventive treatment, on May 3, 2024. The study didn’t meet its primary goal, as the medication’s effectiveness was not statistically significant when compared to a placebo. Despite the expected decrease in monthly migraine days for the treatment arms, the placebo arm showed an unexpectedly high decrease, blurring the treatment’s perceived benefits. These results suggest more research is needed to assess ABP-450’s true efficacy.

Learn more about AEON stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAEON Biopharma Releases New Investor Presentation
TheFlyAeon Biopharma announces outcome from FDA biosimilar advisory meeting
TheFlyAeon Biopharma files $200M mixed securities shelf
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App